Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes

BMC Endocrine Disorders - Tập 23 Số 1
Zhen Liu1, Yue Peng2, Supeng Li1, Yu‐Sheng Lin2, Yunfeng Huang2, Wenting Chen3, Chunhua Bao3, Zengxian Zhou1, Lin Zeng2,4,1, Liangmiao Chen3
1School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China
2Department of Cardiology, The 1st affiliated Hospital of Wenzhou Medical Unversity, Wenzhou, China
3Department of Endocrinology, The 3rd affiliated Hospital of Wenzhou Medical University (Ruian People’s Hospital, Wenzhou, China
4Laboratory Animal Center of Wenzhou Medical University, Wenzhou, China

Tóm tắt

Abstract Objectives Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by chronic hyperglycemia and metabolic stress, involved in the stepwise development of cardiovascular complications. Fibroblast growth factor 21 (FGF21) is a novel hepatokine involved in regulating glucose and lipid metabolism, and has been linked to the prediction, treatment, and improvement of prognosis in multiple cardiovascular diseases (CVDs). The aim of this study is to explore the relationship between FGF21 levels and vascular diseases (VDs) including carotid atherosclerosis (CAS) and hypertension (HP) in patients with T2DM. Methods Baseline serum FGF21 was determined in a cross-sectional study of 701 patients with T2DM and 258 healthy control. Results The morbidity of CAS was increased in T2DM patients with HP as compared with those without (p < 0.001). The average serum FGF21 level of healthy was [123.9 (67.2-219.3)]. Baseline FGF21 was significantly higher in those who developed CAS or HP than in those who did not [305.9 (177.2-508.4) vs. 197.2 (129.7-308.3) pg/mL, p < 0.001]. In addition, an elevated serum FGF21 was observed in T2DM patients with HP and CAS than that of T2DM patients with CAS or HP [550.5 (312.6-711.3) vs. 305.9 pg/mL, p < 0.001]. Serum FGF21 levels were positively correlated with body mass index and carotid intima media thicknes (p < 0.05), the association remained significant after adjusting for age and T2DM duration. Furthermore, the multinomial logistic regression showed that serum FGF21 was independently associated with CAS and HP in patients with T2DM after adjustment for demographic and traditional VDs risk factors (p < 0.001). Conclusions Baseline FGF21 is elevated in VDs during diabetes, changes of serum FGF21 levels were appropriately matched to metabolic stress. FGF21can be used as an independent predictor for diagnosing VDs and predicting prognosis.

Từ khóa


Tài liệu tham khảo

Chen Y, Zhao X, Wu H. Metabolic stress and Cardiovascular Disease in Diabetes Mellitus: the role of protein O-GlcNAc modification. Arterioscler Thromb Vasc Biol. 2019;39(10):1911–24. https://doi.org/10.1161/ATVBAHA.119.312192.

Gonzalez LL, Garrie K, Turner MD. Type 2 Diabetes - an autoinflammatory Disease driven by metabolic stress. Biochim Biophys Acta Mol Basis Dis. 2018;1864(11):3805–23. https://doi.org/10.1016/j.bbadis.2018.08.034.

Vinciguerra F, Baratta R, Farina MG, Tita P, Padova G, Vigneri R, et al. Very severely obese patients have a high prevalence of type 2 Diabetes Mellitus and Cardiovascular Disease. Acta Diabetol. 2013;50(3):443–9. https://doi.org/10.1007/s00592-013-0460-3.

Zhang Y, Liu D, Long XX, Fang QC, Jia WP, Li HT. The role of FGF21 in the pathogenesis of Cardiovascular Disease. Chin Med J (Engl). 2021;134(24):2931–43. https://doi.org/10.1097/CM9.0000000000001890.

Samms RJ, Cheng CC, Fourcaudot M, Heikkinen S, Khattab A, Adams J, et al. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 Diabetes. Am J Physiol Endocrinol Metab. 2022;323(2):E123–32. https://doi.org/10.1152/ajpendo.00050.2022.

Huang S, Wu B, He Y, Qiu R, Yang T, Wang S, et al. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. Hepatol Commun. 2023;7(3):e0045. https://doi.org/10.1097/HC9.0000000000000045.

Szczepańska E, Gietka-Czernel M. FGF21: a Novel Regulator of glucose and lipid metabolism and whole-body Energy Balance. Horm Metab Res. 2022;54(4):203–11. https://doi.org/10.1055/a-1778-4159.

Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J, et al. FGF21 prevents angiotensin II-Induced Hypertension and vascular dysfunction by activation of ACE2/Angiotensin-(1–7) Axis in mice. Cell Metab. 2018;27(6):1323–1337e5. https://doi.org/10.1016/j.cmet.2018.04.002.

Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, et al. Fibroblast growth factor 21 prevents Atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015;131(21):1861–71. https://doi.org/10.1161/CIRCULATIONAHA.115.015308.

Xiao Y, Liu L, Xu A, Zhou P, Long Z, Tu Y, et al. Serum fibroblast growth factor 21 levels are related to subclinical Atherosclerosis in patients with type 2 Diabetes. Cardiovasc Diabetol. 2015;14:72. https://doi.org/10.1186/s12933-015-0229-9.

Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Targeting FGF21 in cardiovascular and metabolic Diseases: from mechanism to medicine. Int J Biol Sci. 2023;19(1):66–88. https://doi.org/10.7150/ijbs.73936.

Lin ZF, Pan XB, Wu F, Zhang Y, Wang C. Application of FGF21 in the preparation of Drugs for the treatment of HP and/or vascular injury caused by angiotensin II. People’s Republic of China, CN108379555. 2018.08.10. No doi or PMID.

Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and Cardiovascular Diseases: going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):e3502. https://doi.org/10.1002/dmrr.3502.

Sun P, Dwyer KM, Merz CN, Sun W, Johnson CA, Shircore AM, et al. Blood pressure, LDL cholesterol, and intima-media thickness: a test of the response to injury hypothesis of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20(8):2005–10. https://doi.org/10.1161/01.atv.20.8.2005.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, Diabetes, Atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52. https://doi.org/10.1016/j.jhep.2017.09.021.

Grimaldi A, Heurtier A. Diagnostic criteria for type 2 Diabetes. Rev Prat. 1999;49(1):16–21. No doi or PMID.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006.

Nonterah EA, Crowther NJ, Klipstein-Grobusch K, Oduro AR, Kavousi M, Agongo G, et al. Racial and Ethnic Differences in the Association between Classical Cardiovascular Risk Factors and common carotid intima-media thickness: an Individual Participant Data Meta-Analysis. J Am Heart Assoc. 2022;11(15):e023704. https://doi.org/10.1161/JAHA.121.023704.

Crouse JR, Harpold GH, Kahl FR, Toole JF, McKinney WM. Evaluation of a scoring system for extracranial carotid Atherosclerosis extent with B-mode ultrasound. Stroke. 1986;17(2):270–5. https://doi.org/10.1161/01.str.17.2.270.

An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 Diabetes Mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012;96(2):196–203. https://doi.org/10.1016/j.diabres.2012.01.004.

Kaihara T, Hoshide S, Tomitani N, Kanegae H, Kario K. Maximum home systolic blood pressure is a marker of carotid Atherosclerosis. Clin Exp Hypertens. 2019;41(8):774–8. https://doi.org/10.1080/10641963.2018.1557678.

Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17(5):779–89. https://doi.org/10.1016/j.cmet.2013.04.005.

Liu X, Zhang Y, Ma C, Lin J, Du J. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty Liver Disease through controlling PPARα/Fgf21 signaling. Mol Biol Rep. 2022;49(4):3113–22. https://doi.org/10.1007/s11033-022-07142-5.

Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Serum levels of FGF-21 are increased in coronary Heart Disease patients and are independently associated with adverse lipid profile. PLoS ONE. 2010;5(12):e15534. https://doi.org/10.1371/journal.pone.0015534.

Yafei S, Elsewy F, Youssef E, Ayman M, El-Shafei M. Fibroblast growth factor 21 association with subclinical Atherosclerosis and arterial stiffness in type 2 Diabetes. Diabetes Metab Syndr. 2019;13(1):882–8. https://doi.org/10.1016/j.dsx.2018.12.007.

Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, et al. Serum fibroblast growth factor-21 levels are associated with carotid Atherosclerosis Independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33(10):2454–9. https://doi.org/10.1161/ATVBAHA.113.301599.

Kaur N, Gare SR, Shen J, Raja R, Fonseka O, Liu W. Multi-organ FGF21-FGFR1 signaling in metabolic health and Disease. Front Cardiovasc Med. 2022;9:962561. https://doi.org/10.3389/fcvm.2022.962561.

Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ. at al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. (2012) 16(3):387 – 93. https://doi.org/10.1016/j.cmet.2012.08.002.

Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and Hypertension. Curr Hypertens Rep. 2017;19(4):28. https://doi.org/10.1007/s11906-017-0730-5.

Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 Diabetes. Cell Metab. 2013;18(3):333–40. https://doi.org/10.1016/j.cmet.2013.08.005.

Shang W, Yu X, Wang H, Chen T, Fang Y, Yang X, et al. Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells. Mol Med Rep. 2015;11(1):503–8. https://doi.org/10.3892/mmr.2014.2731.

Kim WJ, Kim SS, Lee HC, Song SH, Bae MJ, Yi YS, et al. Association between Serum Fibroblast Growth Factor 21 and coronary artery Disease in patients with type 2 Diabetes. J Korean Med Sci. 2015;30(5):586–90. https://doi.org/10.3346/jkms.2015.30.5.58.

Thông tin
Thông tin xuất bản

BMC Endocrine Disorders

Tập 23 Số 1

Thông tin tác giả